|
1. How ‘high-throughput’ cryo-EM technology is utilized to identify functionally superior Lead Candidates. Researchers now can rapidly identify lead candidates at early stages, revealing optimal binding profiles and functional efficacy. This accelerates development timelines and enhances the precision of candidate selection. |
|
2. How large amounts of 3D structural data helps to develop and validate next-gen AI models in Antibody discovery. Structural data not only fuels the development of more robust AI tools but also accelerates and enhances the precision of antibody design and screening processes. and enhances the precision of antibody design and |
|
3. Key Application Examples from ATEM customers & beyond. These case studies demonstrate the versatility and impact of structural insights in accelerating therapeutic development. and hese case studies demonstrate the versatility hese |
ATEM's platform empowers you to evaluate an entire lead series for more informed decision-making
Delivering clear results before lead candidate selection
.png?width=545&height=681&name=Frame%2083%20(2).png)
You might be interested in:
Comparison of cryo-EM vs. orthogonal methods
About the Speaker
& Cryo-EM Expert
Dr. Karl Bertram
Co-Founder & Cryo-EM Scientist
Dr. Karl Bertram earned his PhD and completed his postdoctoral research at the prestigious Max Planck Institute for Biophysical Chemistry, specializing in the 3D structures of human spliceosomes. Leveraging his expertise in cryo-EM, he co-founded ATEM, where he plays a pivotal role in pioneering a groundbreaking cryo-EM platform.
